Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200-Day Moving Average – Should You Sell?

Spero Therapeutics, Inc. (NASDAQ:SPRO) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.25 and traded as high as $2.26. Spero Therapeutics shares last traded at $2.23, with a volume of 682,738 shares trading hands.

Wall Street Analyst Weigh In

SPRO has been the topic of a number of research reports. Wall Street Zen raised Spero Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, January 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spero Therapeutics in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce”.

Spero Therapeutics Stock Performance

The firm has a market cap of $125.64 million, a PE ratio of -2.82 and a beta of 1.45. The company’s 50-day simple moving average is $2.36 and its two-hundred day simple moving average is $2.25.

Insiders Place Their Bets

In other Spero Therapeutics news, insider Esther Rajavelu sold 87,917 shares of the business’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $2.36, for a total transaction of $207,484.12. Following the transaction, the insider directly owned 1,012,091 shares of the company’s stock, valued at approximately $2,388,534.76. The trade was a 7.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.50% of the stock is currently owned by company insiders.

Institutional Trading of Spero Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. purchased a new position in shares of Spero Therapeutics during the 2nd quarter worth approximately $43,000. State Street Corp grew its stake in Spero Therapeutics by 10.1% in the fourth quarter. State Street Corp now owns 210,151 shares of the company’s stock worth $490,000 after purchasing an additional 19,200 shares during the period. Millennium Management LLC bought a new position in Spero Therapeutics in the fourth quarter worth $56,000. Dimensional Fund Advisors LP bought a new stake in shares of Spero Therapeutics during the 3rd quarter valued at $55,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Spero Therapeutics in the 2nd quarter worth about $90,000. 25.60% of the stock is currently owned by hedge funds and other institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.